BRUERA, G., CANNITA, K., GIORDANO, A. V., VICENTINI, R., FICORELLA, C., & RICEVUTO, E. (2013). Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype. D.A. Spandidos.

BRUERA, GEMMA, KATIA CANNITA, ALDO VICTOR GIORDANO, ROBERTO VICENTINI, CORRADO FICORELLA, et ENRICO RICEVUTO. Differential Prognosis of Metastatic Colorectal Cancer Patients Post-progression to First-line Triplet Chemotherapy Plus Bevacizumab, FIr-B/FOx, According to Second-line Treatment and KRAS Genotype. D.A. Spandidos, 2013.

BRUERA, GEMMA, et al. Differential Prognosis of Metastatic Colorectal Cancer Patients Post-progression to First-line Triplet Chemotherapy Plus Bevacizumab, FIr-B/FOx, According to Second-line Treatment and KRAS Genotype. D.A. Spandidos, 2013.